Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Residual entry of selected HIV-1 subtype C Envs in the presence of MVC in NP2-CD4/CCR5 and 293-Affinofile CD4med/CCR5hi cells

From: Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc

Patient ID Env clone Residual entry in NP2 cells (%)a Residual entry in Affinofile cells (%)a
  ADA 0.25 ± 0.04 n.a.
YU2 0.04 ± 0.02 0.26 ± 0.02
JRCSF 0.09 ± 0.02 0.18 ± 0.02
MVCres 37.8 ± 1.01 68.45 ± 14.35
MVCsens 1.82 ± 0.2 47.28 ± 2.23
204 E-7 3.6 ± 0.09 36.24 ± 5.01
550 I-2 3.80 ± 0.71 52.6 ± 13.87
I-7 3.84 ± 1.00 36.2 ± 1.81
F-12 4.32 ± 1.32 60.32 ± 7.20
F-20 2.80 ± 1.11 38.83 ± 4.09
1375 E-2 9.73 ± 2.50 84.20 ± 8.99
I-8 20.34 ± 5.23 69.03 ± 9.10
1441 E-1 5.70 ± 0.47 44.77 ± 2.55
E-2 2.7 ± 1.00 53.69 ± 9.14
E-6 6.72 ± 0.66 67.26 ± 9.58
I-2 3.90 ± 0.49 68.34 ± 11.52
I-9 4.57 ± 0.42 79.78 ± 4.18
1503 F-7 3.37 ± 0.71 n.a.
1684 E-7 2.84 ± 1.74 27.46 ± 3.51
1854 I-7 4.56 ± 0.73 n.a.
2042 I-38 2.95 ± 0.86 38.77 ± 0.53
  1. n.a. not done
  2. aMean % residual entry ± standard deviation from two independent experiments